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Commentary on: Adipocyte-derived endotrophin promotes malignant tumor progression
Collagen VI (COL6, encoded by the COL6A1, 
COL6A2, and COL6A3 genes) is an extracellular matrix 
protein that forms a microfilamentous network in various 
connective tissues, including skeletal muscle, cartilage, 
skin and adipose tissue. Among the various tissues, 
adipose tissue is by far the most abundant source of COL6 
microfilaments [1]. Clinically, mutations in COL6 develop 
mild muscle myopathies (such as Bethlem myopathy and 
Ullrich congenital muscular dystrophy), with symptoms 
of muscle weakness and apoptosis combined with joint 
hyperlaxity and contractures [2]. A genetically engineered 
mouse model, deficient in COL6 microfilament formation 
and secretion, has been widely used to investigate the roles 
of COL6 under physiological and pathological conditions. 
COL6 deficiency in mice leads to the development of 
muscle dystrophies resembling Bethlem myopathy in 
man [3]. In the area of tumor biology, COL6 has been 
identified as a tumor-promoting factor abundantly 
produced and released from adipocytes [4]. Subsequent 
analysis of the COL6 functional null mice bred into the 
murine MMTV-PyMT mammary tumor model (mouse 
mammary tumor virus-polyoma middle T antigen) 
showed a significant attenuation of early onset mammary 
tumor progression [5]. Specifically, the carboxyl-terminal 
domain of the COL6A3 chain is massively upregulated 
in the malignant tumors of human patients compared to 
the remaining part of COL6A3 chain [5]. We recently 
followed up on this phenomenon and demonstrated that 
the cleavage product from the carboxyl-terminus of the 
COL6A3 chain (that we refer to as endotrophin) accounts 
for the tumor-promoting effects associated with COL6 [6]. 
Ectopic expression of the isolated endotrophin fragment 
within the tumor microenvironment of MMTV-PyMT 
mice drives an increase of both primary tumor growth 
and pulmonary metastasis through an enhancement of the 
expansion of the tumor stroma [6]. Additional prominent 
effects associated with endotrophin overexpression in the 
tumor stroma include an increase in fibrosis, angiogenesis 
and inflammation through increased fibrogenesis, a 
stimulation of epithelial-mesenchymal transition (EMT) 
and chemokine activities; these are well-established 
stromal phenomena that support aggressive traits of 
tumors (Figure 1). Indeed, neutralizing monoclonal 
antibodies against endotrophin suppress tumor growth and 
reduce metastatic growth in MMTV-PyMT mice [6]. EMT 
of tumors conveys metastatic traits and multiple drug 
resistances to cancer cells. Since endotrophin is a potent 
stimulator of EMT, it suggests that the neutralization of 
endotrophin may lend itself to enhance chemo-sensitivity 
in combination with conventional therapeutic regimens, 
though this remains to be directly shown.
Adipose tissue is a crucial organ for the maintenance 
of whole body energy homeostasis, and also a major 
source of COL6. We have therefore explored the roles 
of COL6 in metabolic homeostasis even without a tumor 
burden. Metabolic characterization of the COL6A1 
functional null mice bred with a genetically obese animal 
model, the ob/ob mouse, reveals that COL6 deficiency 
improves systemic metabolic profiles, including enhanced 
insulin sensitivity and glucose metabolism. This is likely 
due to a number of changes, but the reduced fibrotic stress 
commonly seen in hypertrophic adipose tissues in obese 
status is likely to be a contributing factor [7]. COL6 is 
upregulated in obese and dysfunctional adipose tissue, and 
anti-diabetic treatment regimens lead to a suppression of 
COL6 expression. Tumor lesions in the microenvironment 
lead to a further local enrichment of endotrophin, either 
through stimulation of syntheses and/or cleavage 
of endotrophin from the mature protein, or through 
an induction of production within the tumor lesions 
themselves. As such, endotrophin is likely to constitute 
one of the risk factors that mediate the more aggressive 
lesion growth and worse prognosis seen in patients with 
higher body mass indices (BMIs). More importantly, it 
is likely that endotrophin plays a pro-fibrotic and pro-
inflammatory role in a number of additional tissues, 
even in the absence of a tumor challenge. This may be 
relevant for adipose tissues, liver and kidney, all tissues 
that are prone to fibrosis and chronic inflammation 
under pathological conditions. Therefore, inhibition of 
endotrophin activity under such pathological conditions is 
likely to be associated with clinical improvements.
Two important issues remain to be resolved. 
These include the question as to which matrix 
metalloproteinase(s) (MMPs) specifically cleave 
endotrophin from its parent COL6A3 chain. Furthermore, 
a second important question is which cell surface proteins 
act as receptors to mediate endotrophin action, leading 
to downstream signaling events triggering the enhanced 
TGFβ signaling and the chemokine action. Answers 
to these questions will have a significant impact on our 
understanding of the significance of endotrophin under 
normal and pathological conditions.
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Figure 1: Endotrophin-mediated changes in the tumor 
stroma. Adipocyte-derived COL6A3 levels are increased during 
obesity. Endotrophin is cleaved from the COL6A3 parent chain 
within the tumor microenvironment. Endotrophin potentiates 
TGFβ-dependent epithelial-mesenchymal transition (EMT) 
and fibrosis and displays chemoattractive activity, recruiting 
endothelial cells and macrophages, leading to enhanced 
angiogenesis and chronic inflammation. All of these activities 
induced by endotrophin synergistically lead to enhanced tumor 
growth and metastasis. Either the endotrophin neutralizing 
monoclonal antibody (10B6) or the TGFβ antagonizing 
monoclonal antibody (1D11) differentially attenuate a subset of 
endotrophin effects. EndoRc: endotrophin receptor.
